Correction: An earlier version of this article erroneously stated that Ezekowitz would be leaving Lankenau.
Michael Ezekowitz is joining the Cardiovascular Research Foundation (CRF) in New York City to start a new center for atrial fibrillation research. Ezekowitz, a cardiologist at the Lankenau Institute for Medical Research in Philadelphia, had been a professor and vice president for clinical research at Lankenau. Recently, Ezekowitz was a co-principal investigator of the RE-LY trial of dabigatran versus warfarin for stroke prevention in AF patients. Ezekowitz went to medical school in South Africa, received a D. Phil from Imperial College at London University, and completed his cardiology fellowship at Johns Hopkins.
Ezekowitz’s appointment represents a new area of interest for CRF, which has traditionally focused on procedures and devices associated with interventional cardiology. The CRF’s Gregg Stone told CardioBrief:
We’ve always had an intense interest in the intersection between pharmacotherapy and interventional cardiology. Atrial fibrillation management has emerged as an entity that may be treated with pharmacology, intervention (left atrial appendage closure), EP ablation and/or surgery – so this area is a natural for CRF. Mike is one of the world’s foremost authorities on the management of patients with atrial fibrillation, having led or been involved with many of the seminal studies in Afib over his distinguished career. We are very pleased that he has brought his prodigious talents to CRF.